口服依托泊苷用于经治转移性乳腺癌的疗效
Medicine(Baltimore).May;94(17):e.
EfficacyoforalEtoposideinpretreatedmetastaticbreastcancer:amulticenterphase2study.
YuanP,DiL,ZhangX,YanM,WanD,LiL,ZhangY,CaiJ,DaiH,ZhuQ,HongR,XuB.
DepartmentofMedicalOncology,CancerInstituteandHospital,ChineseAcademyofMedicalSciencesandPekingUnionMedicalCollege.
PekingUniversityCancerHospital.
PekingUnionMedicalCollegeHospital,Beijing.
HenanCancerHospital,Zhengzhou.
China-JapanFriendshipHospital,Beijing.
FirstAffiliatedHospitalofDalianMedicalUniversity(LL),Dalian.
BeijingHospitaloftheMinistryofHealth.
ZhejiangCancerHospital.
BeijingChaoYangHospital,Beijing.
ShanghaiPutuoDistrictPeoplesHospital,Shanghai,China.
Nostandardchemotherapyhasbeendefinedformetastaticbreastcancer(MBC)patientspretreatedwithanthracyclinesandtaxanes.Amulticenterphase2studywasconductedtoevaluatethesafetyandefficacyoforaletoposideinpatientswithMBC.Eligiblepatientsweretreatedwithrepeatedcyclesoforaletoposide(60mg/m/dondays1-10,followedby11daysofrest).Theprimaryendpointwasprogression-freesurvival(PFS).Thesecondaryendpointswereobjectiveresponserate,clinicalbenefitrate(CBR),andtoxicityprofiles.Seventy-fivewomenwithMBCwereenrolledat10centersinChina.Seven(9.3%)patientsachievedpartialresponse(PR)and29(38.7%)hadstabledisease(SD).Ninepatients(12%)hadSDfor24weeksandtheCBRwas21.3%(16/75).ThemedianPFSwas4.5(range,1.3-7.7)months.Ofthe38patientswhoreceived≥3regimenspriortothisstudy,2(5.3%)hadPRand3(7.9%)hadSDfor24weeks,withaCBRof13.2%.Thereportedgrade3/4adverseeventsincludedleukopenia(13.3%,n=10),neutropenia(17.9%,n=14),anemia(2.7%,n=2),vomiting(2.6%,n=2),andalopecia(1.3%,n=1).OraletoposidewaseffectiveandwelltoleratedinChinesewomenwithpretreatedMBC.
PMID:
DOI:10./MD.0
赞赏
长按
